Department of Microbiology, Immunology and Transplantation, Nephrology and Renal Transplantation Research Group, KU Leuven, 3000 Leuven, Belgium.
Department of Medicine, Division of Nephrology, University Hospitals Leuven, 3000 Leuven, Belgium.
J Clin Endocrinol Metab. 2022 Nov 25;107(12):e4350-e4359. doi: 10.1210/clinem/dgac522.
Parathyroid hormone (PTH) treatment targets for patients receiving hemodialysis (HD) are lower in Japan than in Europe. Whether this translates to lower bone turnover is unknown and could depend on skeletal PTH responsiveness.
This study investigates whether skeletal PTH responsiveness is better preserved in Japanese vs European patients receiving HD.
This is a post hoc analysis of data from 2 prospective cohort studies, using a case-control design. Patients receiving chronic intermittent HD therapy were eligible for inclusion. Participating Belgian and Japanese patients (n = 374) were matched 1:1 by age (59 ± 12 years), sex (66% male), diabetes (34%), and dialysis duration (39 months [22-63 months]). PTH, bone-specific alkaline phosphatase (BALP), and tartrate-resistant acid phosphatase isoform 5b (TRAP5b) were measured centrally in Liège, Belgium.
Japanese patients had lower levels of iPTH (207 vs 268 pg/mL; P < .001), BALP (15.3 vs 24.5 μg/L; P < .001), and TRAP5b (3.35 vs 5.79 U/L; P < .001). Linear regression analyses revealed lower levels of bone turnover markers for any given level of PTH in Japanese vs Belgian patients, indicating lower skeletal PTH responsiveness. Consistently, bone turnover markers were significantly lower in Japanese vs Belgian patients when stratifying or matching according to PTH levels. Male sex, obesity, and hyperphosphatemia were the main determinants of the bone turnover marker/PTH ratios.
Japanese patients receiving HD have lower bone turnover than their European counterparts, even at similar PTH levels. The rationale for the current regional differences in PTH treatment targets remains obscure and deserves further attention.
与欧洲相比,日本接受血液透析(HD)治疗的患者甲状旁腺激素(PTH)的治疗目标更低。这种情况是否会导致骨转换率降低尚不清楚,这可能取决于骨骼对 PTH 的反应性。
本研究旨在探讨日本和欧洲接受 HD 治疗的患者中,骨骼对 PTH 的反应性是否更好地保留。
这是两项前瞻性队列研究数据的事后分析,采用病例对照设计。接受慢性间歇性 HD 治疗的患者符合纳入标准。参与比利时和日本研究的患者(n=374)按年龄(59±12 岁)、性别(66%为男性)、糖尿病(34%)和透析时间(39 个月[22-63 个月])1:1 匹配。PTH、骨碱性磷酸酶(BALP)和抗酒石酸酸性磷酸酶 5b(TRAP5b)在比利时列日进行中心检测。
日本患者的 iPTH(207 比 268 pg/ml;P<0.001)、BALP(15.3 比 24.5 μg/L;P<0.001)和 TRAP5b(3.35 比 5.79 U/L;P<0.001)水平均较低。线性回归分析显示,与比利时患者相比,日本患者在任何给定的 PTH 水平下,骨转换标志物的水平均较低,表明骨骼对 PTH 的反应性较低。当根据 PTH 水平进行分层或匹配时,日本患者的骨转换标志物显著低于比利时患者。男性、肥胖和高磷血症是骨转换标志物/PTH 比值的主要决定因素。
与欧洲患者相比,接受 HD 治疗的日本患者的骨转换率更低,即使在相似的 PTH 水平下也是如此。目前 PTH 治疗目标在不同地区存在差异的原因仍不清楚,值得进一步关注。